In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity

Stem Cells

Volumn 17, Issue 6, 1999, Pages 345-356

  Mayhew, Christopher N ^a,b   Phillips, Jonathan D ^a   Greenberg, Richard N ^b   Birch, Nicholas J ^c,d   Elford, Howard L ^f   Gallicchio, Vincent S ^b,e  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Academic Consultancy Services Limited   (United Kingdom)

^d Molecules for Health Inc   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f NONE

Author keywords

Bone marrow; Burst forming unit erythroid; Colony forming unit granulocyte macrophage; Didox; Hematopoiesis; HIV 1; Hydroxyurea; Ribonucleotide reductase inhibitors; Toxicity; Trimidox

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZAMIDOXIME; ANTIVIRUS AGENT; HYDROXYUREA; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; DRUG EFFECT; DRUG POTENCY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MEAN CORPUSCULAR HEMOGLOBIN; MOUSE;

EID: 0032757206     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.170345     Document Type: Article

References (57)

1. Barry M, Mulcahy F, Back DJ. Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol 1998;45:221-228.
2. Carpenter CC, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
3. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
4. Palella FJJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
5. Gunthard HF, Wong JK, Ignacio CC et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
6. Shafer RW, Winters MA, Palmer S et al. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998;128:906-911.
7. Wong JK, Gunthard HF, Havlir DV et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997;94:12574-12579.
8. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
9. Furtado MR, Callaway DS, Phair JP et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
10. Carr A, Samaras K, Chisholm DJ et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736.
11. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
12. Ho TT, Chan KC, Wong KH et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736-1737.
13. Gao WY, Cara A, Gallo RC et al. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8928.
14. Lori F, Malykh A, Cara A et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-805.
15. Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-772.
16. Malley SD, Grange JM, Hamedi-Sangsari F et al. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-11021.
17. Gao WY, Mitsuya H, Driscoll JS et al. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2′-beta-fluoro-2′,3′-dideoxyadenosine in peripheral blood mononuclear cells. Biochem Pharmacol 1995;50:274-276.
18. Giacca M, Borella S, Calderazzo F et al. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′-azido-3′-deoxythymidine on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses 1996;12:677-682.
19. Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999;43:2046-2050.
20. Biron F, Lucht F, Peyramond D et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:36-40.
21. Biron F, Lucht F, Peyramond D et al. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 1996;29:111-113.
22. Montaner JS, Zala C, Conway B et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-806.
23. Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-F77.
24. Lori F, Jessen H, Lieberman J et al. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999;15:619-624.
25. Giacca M, Zanussi S, Comar M et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-209.
26. Simonelli C, Nasti G, Vaccher E et al. Hydroxyurea treatment in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:462-464.
27. Belt RJ, Haas CD, Kennedy J et al. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 1980;46:455-462.
28. Veale D, Cantwell BM, Kerr N et al. Phase I study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol 1988;21:53-56.
29. Smith DC, Vaughan WP, Gwilt PR et al. A phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother Pharmacol 1993;33:139-143.
30. Newman EM, Carroll M, Akman SA et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol 1997;39:254-258.
31. Foli A, Lori F, Maserati R et al. Hydroxyurea and didanosine as a more potent combination than hydroxyurea and zidovudine. Antiviral Ther 1997;2:33-40.
32. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 1968;33:129-135.
33. van't Riet B, Wampler GL, Elford HL. Synthesis of hydroxy-and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J Med Chem 1979;22:589-592.
34. Elford HL, van't Riet B. Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives. Pharmacol Ther 1985;29:239-254.
35. Szekeres T, Gharehbaghi K, Fritzer M et al. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 1994;34:63-66.
36. Fritzer-Szekeres M, Novotny L, Romanova D et al. Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. Life Sci 1998;63:545-552.
37. Mayhew C, Oakley O, Piper J et al. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddl) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). Cell Mol Biol (Noisy-le-grand) 1997;43:1019-1029.
38. Mills DL, Elford HL, van't Riet B et al. Didox and analogs are effective against retrovirus in a murine model. Antivir Res 1992;17(suppl 1):76.
39. van't Riet B, Wampler CL, Elford HL. Polyhydroxybenzoic acid derivatives. 1990: USA Patent # 4,942,253.
40. Elford HL, Wampler GL, van't Riet B. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 1979;39:844-851.
41. Mills DL, Elford HL, van't Riet B et al. Didox exhibits antiviral activity in a retrovirus animal model. Proc Am Assoc Cancer Res 1992;33:399.
42. Ussery MA, Kunder SC, Goldberg G et al. In vitro antiretroviral activity of ribonucleotide reductase inhibitors hydroxyurea, Didox and Trimidox in the HIV-infected HuPBMC SCID model and the Rauscher murine leukemia virus (RMuLV) model: mono-and combination therapy. Intersci Conf Antimicrob Agents Chemother, 1996:188.
43. Szekeres T, Fritzer-Szekeres M, Elford HL. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 1997;34:503-528.
44. Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998;55:1551-1556.
45. Romanelli F, Pomeroy C, Smith KM. Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Pharmacotherapy 1999;19:196-204.
46. Meyerhans A, Vartanian JP, Hultgren C et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-540.
47. Lori F, Malykh AG, Foli A et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-1409.
48. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19:11-19.
49. Uyeki EM, Pazdernik TL, el Ashkar A. Toxicity of antitumor agents on hemopoietic colony forming cells. J Pharmacol Exp Ther 1976;198:246-253.
50. Necas E, Neuwirt J. Proliferation rate of haemopoietic stem cells after damage by several cytostatic agents. Cell Tissue Kinet 1976;9:479-487.
51. Dumenil D, Sainteny F, Frindel E. Some effects of chemotherapeutic drugs on bone marrow stem cells. I. The long-term effects of phase-specific drugs on mouse bone marrow stem cells. Cancer Chemother Pharmacol 1979;2:197-201.
52. Moore EC, Hurlbert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol Ther 1985;27:167-196.
53. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10.
54. Carmichael J, Cantwell BM, Mannix KA et al. A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 1990;61:447-450.
55. Veale D, Carmichael J, Cantwell BM et al. A phase I and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer 1988;58:70-72.
56. Rubens RD, Kaye SB, Soukop M et al. Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 1991;64:1187-1188.
57. Elford HL, van't Riet B, Wampler GL et al. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Adv Enzyme Regul 1980;19:151-168.